Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-716
- Sponsors Merck Sharp & Dohme
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 12 Sep 2018 Status changed from not yet recruiting to recruiting.
- 30 Aug 2018 Planned initiation date changed from 28 Sep 2018 to 14 Sep 2018.